TrippBio, a biotechnology company, is producing a patent-pending repurposed FDA-approved drug called TD213 intended for the treatment of viral infections, initially targeting COVID-19, it was reported on Monday.
TD213 is administered orally twice daily and works by halting the SARS-CoV-2 virus and the associated acute inflammatory response to the infection.
The firm has revealed positive interim data from the investigator-initiated study to evaluate the efficacy of the product in treating patients with confirmed mild-moderate COVD-19.
Dr Moti N. Ramgopal of Midway Immunology and Research Center conducted the study. Outpatients who tested positive using a validated SARS-CoV-2 RNA COVID-19 test were administered the product twice daily for 14 days and will be followed until day 28.
Autonomix Medical secures new US patent to expand precision nerve-targeted therapies
Oxford BioDynamics and UEA develop 96% accurate blood test for Chronic Fatigue Syndrome
Merck completes acquisition of Verona Pharma to expand cardio-pulmonary portfolio
Celltrion launches AVTOZMA IV in the United States following FDA approval
Novartis to launch US direct-to-patient platform for Cosentyx
Vascarta completes VAS-101 osteoarthritis clinical trial
Sen-Jam Pharmaceutical and KVK Tech complete final development deliverables for SJP-002C
OSE Immunotherapeutics forms strategic alliance with Inserm Transfert and Nantes University
ResVita Bio completes face-to-face Pre-IND meeting with FDA for RVB-003